Although LC3B levels were markedly reduced in the PD group and strongly correlated with imaging data, clinical parameters and other CSF biomarkers in our study, the alteration in the LC3B level in the CSF was also observed in the two studies mentioned above. This evidence concerns the gene MAP1LC3B and Parkinson disease.